Form 4: Lineage Cell Therapeutics Grants New Stock Options to Director and 10% Owner Neal C. Bradsher

Lineage Cell Therapeutics, Inc. has granted 75,000 stock options to Director and 10% Owner Neal C. Bradsher as part of his director compensation, aligning his interests with shareholder value.

Summary

• Neal C. Bradsher, a Director and 10% Owner of Lineage Cell Therapeutics, Inc. (LCTX), was granted 75,000 options to purchase common shares.
• The newly granted options have an exercise price of $0.8977 per share.
• The grant date for these options was July 1, 2025, and they are set to expire on July 1, 2035.
• These options will vest and become exercisable on the earlier of July 1, 2026, or the date of Lineage Cell Therapeutics, Inc.'s next annual meeting of shareholders after the grant date, subject to Mr. Bradsher's continuous service with the Issuer.
• The grant was made as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.
• Mr. Bradsher also beneficially owns other direct options to purchase common shares, which are currently exercisable, with exercise prices ranging from $0.8263 to $2.86 and expiration dates between June 30, 2029, and July 1, 2034.

Sentiment

Score: 6

Explanation: The grant of stock options to a director and 10% owner is a standard practice that aligns insider interests with shareholder value, indicating a commitment to long-term performance. It is a routine compensation event rather than a significant operational or financial announcement.

Positives

• The grant of 75,000 stock options to Director and 10% Owner Neal C. Bradsher aligns his interests with the long-term performance and shareholder value of Lineage Cell Therapeutics, Inc.
• The options were granted as part of director compensation under an existing equity incentive plan, indicating a structured and approved approach to executive incentives.
• The vesting schedule, tied to continuous service, encourages long-term commitment and retention of a key insider.

Negatives

• Potential for future share dilution if the options are exercised, which is a standard consideration for equity compensation.

Future Outlook

The grant of stock options to Neal C. Bradsher, with a vesting schedule tied to continuous service, indicates an expectation of his ongoing involvement and contribution to Lineage Cell Therapeutics, Inc. The options provide a long-term incentive for him to contribute to the company's future growth and shareholder value.

Management Comments

• These options were granted to the Reporting Person by the Issuer on July 1, 2025 as director compensation pursuant to the Issuer's 2021 Equity Incentive Plan, as amended.

Industry Context

In the biotechnology and cell therapeutics industry, equity compensation, such as stock options, is a common practice to attract, retain, and incentivize key personnel, including directors. This practice aligns the interests of insiders with those of shareholders, encouraging long-term value creation in a capital-intensive and research-driven sector.

Comparison to Industry Standards

• The grant of stock options to a director is a standard practice in publicly traded companies, particularly within the biotechnology sector, where long-term incentives are crucial for retaining talent and aligning interests.
• While specific comparable companies or projects are not detailed in this filing, the use of an equity incentive plan for director compensation is consistent with corporate governance norms for companies like Lineage Cell Therapeutics, Inc.
• The exercise prices and number of options granted would typically be evaluated against peer group compensation practices, which are not provided in this document.

Corporate Governance

Related Party Transactions

• The grant of 75,000 stock options to Neal C. Bradsher, a Director and 10% Owner, constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant of options aligns the interests of a significant insider with long-term shareholder value, potentially encouraging decisions that benefit the stock price. However, future exercise of options could lead to minor dilution.
• Employees: While not directly impacting all employees, the use of an equity incentive plan for director compensation reflects a broader corporate strategy for incentivizing key personnel.

Next Steps

• Vesting of the newly granted 75,000 options on the earlier of July 1, 2026, or the date of the next annual meeting of shareholders, subject to continuous service.
• Potential future exercise of the granted options by Neal C. Bradsher.

Key Dates

Recommendation

Keywords

Lineage Cell Therapeutics, LCTX, SEC Form 4, stock options, director compensation, insider ownership, beneficial ownership, equity incentive plan, corporate governance